International Stem Cell (ISCO) Revenue (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Revenue of $2.2 million for Q4 2025, down 11.9% year-over-year from $2.4 million in Q4 2024, and down 9.03% quarter-over-quarter from $2.4 million in Q3 2025.
International Stem Cell (ISCO) Revenue (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Revenue for 16 consecutive years, with $2.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Revenue fell 11.9% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $9.1 million (changed 0.17% YoY), while the FY2025 annual figure was $9.1 million, changed 0.17% from the prior year.
- Revenue eased to $2.2 million in Q4 2025 per ISCO's latest filing, from $2.4 million in the prior quarter.
- Across five years, Revenue topped out at $2.4 million in Q2 2025 and bottomed at $1.7 million in Q1 2021.
- Historically, Revenue has averaged $2.1 million across 5 years, with a median of $2.1 million in 2022.
- Annual changes were most pronounced in 2021 — Revenue retreated 29.75% — and 2022, when it surged 31.85%.
- International Stem Cell's Revenue stood at $1.8 million in 2021, then jumped by 31.85% to $2.4 million in 2022, then dropped by 22.26% to $1.9 million in 2023, then rose by 29.49% to $2.4 million in 2024, then declined by 11.9% to $2.2 million in 2025.
- Business Quant data shows ISCO's Revenue at $2.2 million in Q4 2025, $2.4 million in Q3 2025, and $2.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 2.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.68 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 2.37 Mn |
| Jun 30, 2025 | 2.45 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 2.43 Mn |
| Sep 30, 2022 | 1.70 Mn |
| Jun 30, 2022 | 2.03 Mn |
| Mar 31, 2022 | 2.02 Mn |
| Dec 31, 2021 | 1.84 Mn |
| Sep 30, 2021 | 1.84 Mn |
| Jun 30, 2021 | 1.83 Mn |